Affordable Access

deepdyve-link
Publisher Website

Infliximab in treatment of idiopathic refractory childhood pyoderma gangrenosum (PG).

Authors
  • Salehzadeh, Farhad1
  • Mohammadikebar, Yusef2
  • Enteshary, Afsaneh2
  • Ghanbarpour, Omid1
  • Mirzarahimi, Mehrdad1
  • 1 Department of Pediatric, Bouali Children's Hospital, Ardabil University of Medical Sciences (ARUMS), Ardabil, Iran. , (Iran)
  • 2 Department of Internal Medicine, Emam Khomeini Hospital, Ardabil University of Medical Sciences (ARUMS), Ardabil, Iran. , (Iran)
Type
Published Article
Journal
Biologics : targets & therapy
Publication Date
Jan 01, 2019
Volume
13
Pages
97–99
Identifiers
DOI: 10.2147/BTT.S203753
PMID: 31239637
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

We report a case of refractory idiopathic childhood pyoderma gangrenosum in a young boy who had suffered from this disease since 3 years of age. He had unfavorable responses and intermittent relapses under different combinations of cytotoxic and steroid therapies. Although there was not much information available about infliximab use for biologic and childhood pyoderma gangrenosum, eventually we decided to use infliximab in this patient. Infliximab showed a dramatic response and resulted in full recovery during 2 years' follow-up.

Report this publication

Statistics

Seen <100 times